Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Apr 1;40(4):467-478.
doi: 10.1097/QAD.0000000000004408. Epub 2025 Nov 14.

Behavioural trajectories following DAA treatment for HCV among people with HIV: findings from an international consortium of prospective cohort studies

Kris Hage  1   2   3 , Joanne Carson  4 , Samira Hosseini-Hooshyar  4 , Rachel Sacks-Davis  5   6   7 , Ashleigh C Stewart  5   6 , Daniela K Van Santen  1   5   6 , Colette Smit  8 , Marc Van Der Valk  3   8 , Linda Wittkop  9   10   11 , Marina B Klein  12 , Joseph S Doyle  5   13 , Andri Rauch  14 , Gail V Matthews  4 , Margaret E Hellard  5   6   7 , Anders Boyd  1   2   8 , Maria Prins  1   2   3 ; InCHEHC study group
Affiliations

Behavioural trajectories following DAA treatment for HCV among people with HIV: findings from an international consortium of prospective cohort studies

Kris Hage et al. AIDS. .

Abstract

Objective: Examine the proportion of people with HIV engaging in behaviours associated with hepatitis C virus (HCV) infection after successful direct-acting antiviral (DAA) treatment and establish longitudinal patterns of behavioural risk over time.

Design: Multinational, prospective cohort study (International Collaboration on Hepatitis C Elimination in HIV Cohorts).

Methods: Individuals with HIV successfully treated with DAAs and ≥2 follow-up visits with behavioural data were included. Changes in the proportion of any risk behaviour after treatment, which included sexual and drug use behaviours, were analysed using logistic regression with generalized estimating equations. We identified distinct trajectories of any risk behaviour over time using group-based trajectory models (GBTM).

Results: Of the 1,477 individuals included, 487 (33.0%) were people who inject drugs, 378 (25.6%) were men who have sex with men and 442 (29.9%) were both. During a median 2.7 years (IQR = 1.6-3.9) of follow-up, the proportion engaging in any risk behaviour slightly decreased over time (adjusted odds ratio per half year = 0.97, 95% confidence interval = 0.95-0.99). GBTM revealed four distinct behavioural trajectories: consistently low ( n = 433, 29.3% of total population), moderate at baseline and increasing ( n = 119, 8.1%), high at baseline and decreasing ( n = 184, 12.5%) and consistently high ( n = 741, 50.2%).

Conclusions: Despite slight decreases in behaviours following successful DAA treatment, half of individuals had a consistently high probability of behaviours that put them at risk of HCV reinfection over time. As reinfections comprise a growing proportion of new incident HCV cases, these findings underscore the importance of ongoing primary prevention measures alongside testing and retreatment to eliminate HCV.

Keywords: HIV; hepatitis C virus; hepatitis C virus-related behaviour; men who have sex with men; people who inject drugs.

PubMed Disclaimer

References

    1. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis . Lancet Infect Dis 2016; 16:797–808.
    1. Polaris Observatory HCVC. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study . Lancet Gastroenterol Hepatol 2022; 7:396–415.
    1. Lingala S, Ghany MG. Natural history of hepatitis C . Gastroenterol Clin North Am 2015; 44:717–734.
    1. CDA Foundation's Polaris Observatory. Available at: https://cdafound.org/polaris/ (Accessed 29 July 2025).
    1. van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, et al. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019 . EClinicalMedicine 2023; 56:101810.

Substances